Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure

JACC: Heart Failure

Volumn 5, Issue 2, 2017, Pages 110-119

  Baras Shreibati, Jacqueline ^a   Goldhaber Fiebert, Jeremy D ^a   Banerjee, Dipanjan ^a   Owens, Douglas K ^a,b   Hlatky, Mark A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

cost effectiveness analysis; heart failure; left ventricular assist device; Medicare

Indexed keywords

ADULT; ANALYTICAL PARAMETERS; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEART FAILURE; HOSPITAL READMISSION; HUMAN; IMPLANTATION; LEFT VENTRICULAR ASSIST DEVICE; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICARE; OUTPATIENT; OUTPATIENT CARE; QUALITY ADJUSTED LIFE YEAR; SIMULATION; AGED; AMBULATORY CARE; ECONOMICS; HEART ASSIST DEVICE; HOSPITALIZATION; LENGTH OF STAY; MARKOV CHAIN; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; UNITED STATES;

CARDIOTONIC AGENT;

AGED; AMBULATORY CARE; CARDIOTONIC AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MARKOV CHAINS; MIDDLE AGED; PATIENT READMISSION; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; UNITED STATES;

EID: 85010685668     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.09.008     Document Type: Article

References (40)

1. 1 Heidenreich, P.A., Albert, N.M., Allen, L.A., et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6 (2013), 606–619.
2. 2 Miller, L.W., Guglin, M., Patient selection for ventricular assist devices: a moving target. J Am Coll Cardiol 61 (2013), 1209–1221.
3. 3 Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 34 (2015), 1495–1504.
4. 4 Boyle, A.J., Ascheim, D.D., Russo, M.J., et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant 30 (2011), 402–407.
5. 5 Estep, J.D., Starling, R.C., Horstmanshof, D.A., et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. J Am Coll Cardiol 66 (2015), 1747–1761.
6. 6 Slaughter, M.S., Rogers, J., Editorial commentary: determining the cost-effectiveness of mechanical circulatory support. J Heart Lung Transplant 31 (2012), 448–449.
7. 7 Rogers, J.G., Bostic, R.R., Tong, K.B., Adamson, R., Russo, M., Slaughter, M.S., Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail 5 (2012), 10–16.
8. 8 Long, E.F., Swain, G.W., Mangi, A.A., Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. Circ Heart Fail 7 (2014), 470–478.
9. 9 Cipriano, L.E., Romanus, D., Earle, C.C., et al. Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value Health 14 (2011), 41–52.
10. 10 Consumer Price Index Inflation Calculator. Bureau of Labor Statistics. U.S. Department of Labor. Available at: http://www.bls.gov/data/inflation_calculator.htm. Accessed May 15, 2016.
11. 11 Akhter, S.A., Badami, A., Murray, M., et al. Hospital readmissions after continuous-flow left ventricular assist device implantation: incidence, causes, and cost analysis. Ann Thorac Surg 100 (2015), 884–889.
12. 12 Ambardekar, A.V., Forde-McLean, R.C., Kittleson, M.M., et al. High early event rates in patients with questionable eligibility for advanced heart failure therapies: results from the Medical Arm of Mechanically Assisted Circulatory Support (MEDAMACS) registry. J Heart Lung Transplant 35 (2016), 722–730.
13. 13 Gold, M.R., Siegel, J.E., Russel, L.B., Weinstein, M.C., Cost-Effectiveness in Health and Medicine. 1996, Oxford University Press, New York, NY.
14. 14 Cowger, J., Shah, P., Stulak, J., et al. INTERMACS profiles and modifiers: Heterogeneity of patient classification and the impact of modifiers on predicting patient outcome. J Heart Lung Transplant 35 (2016), 440–448.
15. 15 Arias, E., United States life tables, 2010. Natl Vital Stat Rep 63 (2014), 1–63.
16. 16 Hasin, T., Marmor, Y., Kremers, W., et al. Readmissions after implantation of axial flow left ventricular assist device. J Am Coll Cardiol 61 (2013), 153–163.
17. 17 Smedira, N.G., Hoercher, K.J., Lima, B., et al. Unplanned hospital readmissions after HeartMate II implantation: frequency, risk factors, and impact on resource use and survival. J Am Col Cardiol HF 1 (2013), 31–39.
18. 18 Slaughter, M.S., Rogers, J.G., Milano, C.A., et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 361 (2009), 2241–2251.
19. 19 Grady, K.L., Naftel, D., Stevenson, L., et al. Overall quality of life improves to similar levels after mechanical circulatory support regardless of severity of heart failure before implantation. J Heart Lung Transplant 33 (2014), 412–421.
20. 20 Post, P.N., Stiggelbout, A.M., Wakker, P.P., The utility of health states after stroke: a systematic review of the literature. Stroke 32 (2001), 1425–1429.
21. 21 Sanders, G.D., Hlatky, M.A., Owens, D.K., Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353 (2005), 1471–1480.
22. 22 Briggs, A.H., Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17 (2000), 479–500.
23. 23 Doubilet, P., Begg, C.B., Weinstein, M.C., Braun, P., McNeil, B.J., Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 5 (1985), 157–177.
24. 24 Feldman, D., Pamboukian, S.V., Teuteberg, J.J., et al. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 32 (2013), 157–187.
25. 25 Wilson, S.R., Givertz, M.M., Stewart, G.C., Mudge, G.H. Jr., Ventricular assist devices the challenges of outpatient management. J Am Coll Cardiol 54 (2009), 1647–1659.
26. 26 Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2304–2322.
27. 27 Yusen, R.D., Christie, J.D., Edwards, L.B., et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report—2013; focus theme: age. J Heart Lung Transplant 32 (2013), 965–978.
28. 28 Kaiser Family Foundation. The Facts on Medicare Spending and Financing. Available at: http://kff.org/medicare/fact-sheet/medicare-spending-and-financing-fact-sheet/. Accessed May 18, 2016.
29. 29 Pagani FD, Milano C, Tatooles A, et al. HeartWare HVAD for the treatment of patients with advanced heart failure ineligible for cardiac transplantation: results of the ENDURANCE destination therapy trial. Paper presented at the 35th Annaul Meeting of the International Society of Heart and Lung Transplantation and Scientific Session. Nice, France; 2015.
30. 30 Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Pump thrombosis in the Thoratec HeartMate II device: an update analysis of the INTERMACS registry. J Heart Lung Transplant 34 (2015), 1515–1526.
31. 31 Freudenberger, R.S., Hellkamp, A.S., Halperin, J.L., et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 115 (2007), 2637–2641.
32. 32 Freeman, J.V., Zhu, R.P., Owens, D.K., et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 154 (2011), 1–11.
33. 33 Pal, J.D., Klodell, C.T., John, R., et al. Low operative mortality with implantation of a continuous-flow left ventricular assist device and impact of concurrent cardiac procedures. Circulation 120 (2009), S215–S219.
34. 34 Milano, C., Pagani, F.D., Slaughter, M.S., et al. Clinical outcomes after implantation of a centrifugal flow left ventricular assist device and concurrent cardiac valve procedures. Circulation 130 (2014), S3–S11.
35. 35 Holloway, R.G., Benesch, C.G., Burgin, W.S., Zentner, J.B., Prognosis and decision making in severe stroke. JAMA 294 (2005), 725–733.
36. 36 Healy, A.H., Stehlik, J., Edwards, L.B., McKellar, S.H., Drakos, S.G., Selzman, C.H., Predictors of 30-day post-transplant mortality in patients bridged to transplantation with continuous-flow left ventricular assist devices—an analysis of the International Society for Heart and Lung Transplantation transplant registry. J Heart Lung Transplant 35 (2016), 34–39.
37. 37 Lund, L.H., Edwards, L.B., Kucheryavaya, A.Y., et al. The registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report-2015: focus theme: early graft failure. J Heart Lung Transplant 34 (2015), 1244–1254.
38. 38 Russo, M.J., Hong, K.N., Davies, R.R., et al. Posttransplant survival is not diminished in heart transplant recipients bridged with implantable left ventricular assist devices. J Thorac Cardiovasc Surg 138 (2009), 1425–1432.
39. 39 Moreno, S.G., Novielli, N., Cooper, N.J., Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation. J Heart Lung Transplant 31 (2012), 450–458.
40. 40 Russo, M.J., Gelijns, A.C., Stevenson, L.W., et al. The cost of medical management in advanced heart failure during the final two years of life. J Card Fail 14 (2008), 651–658.